Shares of Poniard Pharmaceuticals (PARD) -8.8% after the firm said it's replacing its CEO and cutting its work force by 57%. Moves come after disappointing results last week from a Phase II trial of its cancer drug picoplatin. Shares are down 76% over the past three months.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products. For additional information please visit http://www.poniard.com.